Log In
Print
BCIQ
Print
Print this Print this
 

BMN 701 (formerly ZC-701)

  Manage Alerts
Collapse Summary General Information
Company BioMarin Pharmaceutical Inc.
DescriptionFusion of insulin-like growth factor-2 (IGF-2) and acid alpha glucosidase (GAA) that uses Glycosylation Independent Lysosomal Targeting (GILT) technology
Molecular Target Insulin-like growth factor-2 (IGF-2) receptor (IGF2R) (M6PR)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase III
Standard IndicationPompe's disease
Indication DetailsTreat late-onset Pompe's disease; Treat Pompe's disease
Regulatory Designation U.S. - Orphan Drug (Treat Pompe's disease)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$115.0M

$22.0M

$93.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today